CADTH Canadian Drug Expert Committee recommendation: Budesonide (Jorveza--Avir Pharma Inc.) indication : eosinophilic esophagitis
Budesonide has a Health Canada indication for the induction of clinico-pathological remission in adults with EoE. Budesonide is a non-halogenated glucocorticosteroid, which acts primarily as an anti-inflammatory by binding to the glucocorticoid receptor. Budesonide is formulated as a 1 mg orodispers...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, October 2020
|
| Edition: | Version: 1.0 |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Budesonide has a Health Canada indication for the induction of clinico-pathological remission in adults with EoE. Budesonide is a non-halogenated glucocorticosteroid, which acts primarily as an anti-inflammatory by binding to the glucocorticoid receptor. Budesonide is formulated as a 1 mg orodispersible tablet, and the Health Canada-recommended daily dose is 2 mg budesonide asa one 1 mg tablet in the morning and a 1 mg tablet in the evening. The usual treatment duration is six weeks |
|---|---|
| Item Description: | "Final." |
| Physical Description: | 1 PDF file (10 pages) |